ATLANTA, GA / ACCESSWIRE / November 7, 2022 / Holzer & Holzer, LLC is investigating whether Instil Bio, Inc. ("Instil Bio" or the "Company") (NASDAQ:IL) complied with federal securities laws. On October 31, 2022, Instil Bio announced a pause in enrollment in its ongoing clinical trials of ITIL-168 and ITIL-306 due to "a recent decrease in the rate of successful manufacturing of ITIL-168, resulting in the inability to dose some patients whose individual product of ITIL-168 was not successfully manufactured." Following this announcement, the Company's stock price dropped.
If you purchased Instil Bio stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at [email protected] or Joshua Karr, Esq. at [email protected], call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/instil-bio/ to discuss your legal rights.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]
SOURCE: Holzer & Holzer, LLC